MetLife Investment Advisors LLC acquired a new position in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 67,562 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Achillion Pharmaceuticals during the 1st quarter valued at $33,000. Acadian Asset Management LLC purchased a new stake in shares of Achillion Pharmaceuticals in the 4th quarter worth about $41,000. Norges Bank purchased a new stake in shares of Achillion Pharmaceuticals in the 4th quarter worth about $55,000. SG Americas Securities LLC purchased a new stake in shares of Achillion Pharmaceuticals in the 4th quarter worth about $73,000. Finally, BNP Paribas Arbitrage SA grew its position in shares of Achillion Pharmaceuticals by 934.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 31,444 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 28,404 shares during the period. Institutional investors and hedge funds own 79.30% of the company’s stock.
A number of analysts have recently weighed in on ACHN shares. Zacks Investment Research raised shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research report on Tuesday, June 4th. ValuEngine raised shares of Vale from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub cut shares of Ames National from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Barclays set a $24.00 price target on shares of Orion Engineered Carbons and gave the stock a “hold” rating in a research note on Friday, May 3rd. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $2.75.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). As a group, research analysts forecast that Achillion Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Read More: Diversification For Individual Investors
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.